KRT18 and in situ carcinoma: On one hand, CDH1, EPCAM, KRT7, and KRT19 were significantly lower in platinum-resistant variants than in parental cells (p < 0.05); on the other hand, KRT18 was upregulated in IGROV-1 CIS (p = 0.0385), while KRT7 increases in IGROV-1 OHP compared to IGROV-1 (p = 0.0057) and IGROV-1 CIS (p = 0.0001) (Figure 6C).